Literature DB >> 12688327

Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.

José-Tomás Navarro1, Josep-Maria Ribera, José-Luis Mate, Isabel Granada, Jordi Juncà, Montserrat Batlle, Fuensanta Millá, Evarist Feliu.   

Abstract

Hepatosplenic gammadelta T-cell lymphoma (HS-gammadeltaTCL) is an uncommon type of peripheral T-cell lymphoma, which has been associated in some cases with immunosuppression, mainly after solid organ transplants. We describe a case of HSgammadeltaTCL with a leukaemic course in a patient with Crohn's disease who had received azathioprine during the previous 5.5 years. Sinusoidal infiltration by atypical lymphocytes was observed in the liver, spleen and bone marrow and the typical cytogenetic abnormalities (isochromosome 7 and trisomy 8) were found. The patient did not respond to intensive chemotherapy. This case shows the importance of ruling out HSgammadeltaTCL in patients with hepatosplenomegaly, B-symptoms and any immunosuppressive condition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12688327     DOI: 10.1080/1042819021000035662

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  13 in total

Review 1.  [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].

Authors:  G Horneff
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

2.  [Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009].

Authors:  G Horneff; T Hospach; G Dannecker; D Föll; J P Haas; H J Girschick; H I Huppertz; R Keitzer; H J Laws; H Michels; K Minden; R Trauzeddel
Journal:  Z Rheumatol       Date:  2010-08       Impact factor: 1.372

Review 3.  Risks and benefits of biologic therapy for inflammatory bowel diseases.

Authors:  Geert D'Haens
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

4.  Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

Authors:  Stephen B Hanauer
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

Review 5.  Update on the management of Crohn's disease.

Authors:  Anna M Buchner; Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

6.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

Review 7.  Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease.

Authors:  Geoffrey C Nguyen; Mary L Harris; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2006-12

8.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 9.  Infliximab therapy in children and adolescents with inflammatory bowel disease.

Authors:  Gabor Veres; Robert N Baldassano; Petar Mamula
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.

Authors:  María Gómez-García; Maria José Cabello-Tapia; Antonio Damián Sánchez-Capilla; Javier De Teresa-Galván; Eduardo Redondo-Cerezo
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.